You are here: Home: Audio Program Guide: LCU 1 | 2007 Audio: LCU 1 | 2007

  Go to interview with F Anthony Greco, MD
Go to interview with Chandra P Belani, MD
Go to interview with Ronald B Natale, MD
   
  To listen to individual tracks, click the on the track you wish to listen to.
To download tracks, right-click on the one you wish to download.
 
Greco MD F Anthony Greco, MD
Medical Director
Sarah Cannon Cancer Center
Nashville, Tennessee

  
  Click here to download entire interview  
Track 1 Introduction
Track 2 Embryologic theory of cancer of unknown primary
Track 3 Incidence of cancer of unknown primary
Track 4 Use of tumor markers in the identification of cancer of unknown primary
Track 5 Prognosis of cancer of unknown primary
Track 6 Weekly nanoparticle albumin-bound (nab) paclitaxel and carboplatin as first-line therapy for recurrent or advanced non-small cell lung cancer (NSCLC)
Track 7 Shorter infusion time and lack of premedication with nab paclitaxel
Track 8 Dose and schedule of nab paclitaxel
Track 9 Tolerability of and sensory neuropathy with nab paclitaxel
Track 10 Considerations in the use of bevacizumab with first-line chemotherapy
Track 11 Targeting patients for inclusion in adjuvant clinical trials with erlotinib
Track 12 Use of erlotinib with or without chemotherapy in never smokers
Track 13 Clinical trial results of adjuvant chemotherapy in Stage IB NSCLC
Track 14 Selection of adjuvant chemotherapy audio
Track 15 Barriers to clinical trial participation audio
Track 16 Treatment of Stage IIIB NSCLC audio
Track 17 Future directions in the treatment of Stage III disease audio
Track 18 Pemetrexed/gemcitabine with bevacizumab in elderly patients with poor performance status audio
Track 19 Involvement of community oncologists in clinical research audio
 
Belani MD Chandra P Belani, MD
Professor of Medicine
University of Pittsburgh School of Medicine
Co-Director, Lung and Thoracic Malignancies Program
University of Pittsburgh Cancer Institute
Pittsburgh, Pennsylvania

  
  Click here to download entire interview  
Track 1 Introduction
Track 2 Controversies in the adjuvant treatment of Stage IB disease
Track 3 Incorporating bevacizumab into adjuvant clinical trials
Track 4 Use of bevacizumab in clinical practice
Track 5 Use of adjuvant erlotinib in select patients
Track 6 Study of bevacizumab with either chemotherapy or erlotinib compared to chemotherapy alone for recurrent or refractory NSCLC
Track 7 Treatment of Stage III NSCLC
Track 8 New research strategies in Stage III NSCLC
Track 9 Bevacizumab with chemoradiation therapy for Stage III NSCLC
Track 10 Evaluating biologic agents in the metastatic setting
Track 11 Treatment algorithm for metastatic NSCLC
Track 12 Potential advantages of nab paclitaxel
Track 13 Clinical trial strategies with select patients, targeted agents and tissue correlative studies
Track 14 Future directions for clinical research in small cell lung cancer
Track 15 IELCAP study of spiral CT screening for patients at high risk for lung cancer
Track 16 Biomarker discovery and individualized therapy in lung cancer
 
Natale MD Ronald B Natale, MD
Medical Oncologist
Cedars-Sinai Outpatient Cancer Center
Senior Research Advisor and Director
National Lung Cancer Research Program
Aptium Oncology Inc
Los Angeles, California

  
  Click here to download entire interview  
Track 1 Introduction
Track 2 ZD6474 versus gefitinib in patients with advanced NSCLC
Track 3 Efficacy of ZD6474 compared to gefitinib in advanced NSCLC
Track 4 Effect of smoking status on response and clinical benefit
Track 5 Progression-free survival advantage with ZD6474 compared to gefitinib
Track 6 Interpretation, utility and limitations of randomized Phase II studies
Track 7 Impact of potential EGFR inhibitory properties of ZD6474
Track 8 ZD6474 with docetaxel in patients with previously treated NSCLC
Track 9 Lack of ZD6474-associated pulmonary hemorrhages
Track 10 Use of transthoracic radiofrequency ablation under CT guidance to treat bevacizumab-associated pulmonary hemorrhage
Track 11 Predictors of response to EGFR-TK inhibitors audio
Track 12 Use of adjuvant erlotinib in never smokers or those with an EGFR mutation audio
Track 13 Clinical trials evaluating bevacizumab with erlotinib for NSCLC audio
Track 14 Performance status in the selection of patients for treatment with bevacizumab audio
Track 15 Ongoing adjuvant trials incorporating bevacizumab and/or erlotinib audio
Track 16 Impact of CALGB-9633 adjuvant trial in Stage IB NSCLC audio
Track 17 Selection of first-line therapy in patients with NSCLC audio
Track 18 Selection of a taxane for the treatment of metastatic disease audio
Track 19 Chemoradiation regimen for Stage IIIB disease